Impact of Potassium Competitive Acid Blockers After Percutaneous Coronary Intervention for Efficacy and Safety Outcome: Target Trial Emulation Study.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07068490

Acronym

PCAB-PCI

Enrollment

100000

Registered

2025-07-16

Start date

2024-10-22

Completion date

2025-12-31

Last updated

2025-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Artery Disease

Keywords

percutaeneous coronary intervention, dual antiplatelet therapy, gastrointestinal protection

Brief summary

Despite the fact that potassium competitive acid blocker (P-CAB) has been developed for the treatment of gastric ulcer or gastroesophageal reflux disease, the efficacy and safety of P-CAB for the use of gastrointestinal (GI) protection in patients undergoing percutaneous coronary intervention (PCI) and maintaining dual antiplatelet therapy (DAPT) remains uncertain.

Detailed description

To evaluate the efficacy and safety of routine P-CAB use in patients with coronary artery disease who underwent PCI and maintain DAPT, as compared to guideline-directed proton pump inhibitor (PPI) usage.

Interventions

DRUGRoutine use of P-CAB on DAPT

This group received P-CAB with DAPT after PCI.

DRUGGuideline Directed Medical Therapy

This group received PPI or not with DAPT after PCI according to GI bleeding risk.

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Patients who underwent PCI * Use of either clopidogrel, prasugrel, or ticagrelor in combination with aspirin * No use of PCAB, PPI, or an H2-receptor within the past month

Exclusion criteria

* Patients with low GI bleeding risk are taken on PPI * Patients with high GI bleeding risk do not take PPI

Design outcomes

Primary

Measure	Time frame	Description
Major GI bleeding	at 1 year	Major GI bleeding requiring transfusion

Secondary

Measure	Time frame	Description
Clinically relevant GI bleeding	At 1 year	Clinically relevant GI bleeding
Major adverse cardiac event	At 1 year	A composite of cardiovascular death, myocardial infarction, and repeat revascularization
Cardiovascular death	At 1 year	Cardiovascular death
Myocardial infarction	At 1 year	Myocardial infarction
Repeat revascularization	At 1 year	Repeat revascularization

Countries

South Korea

Contacts

Primary ContactKi Hong Choi, MD, PhD

cardiokh@gmail.com82-2-3410-3419

Backup ContactDanbee Kang, PhD

dbee.kang@gmail.com82-2-2148-7197

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026